Aireen

What Aireen does

Aireen a.s. is a Prague-based medical technology company that develops autonomous AI software for retinal screening, analyzing standard 45° fundus images to detect diabetic retinopathy (DR) and age-related macular degeneration (AMD) without requiring ophthalmologist interpretation. Its core product is a hardware-agnostic cloud-based SaaS platform built on deep neural networks trained on approximately 1,000,000 annotated retinal scans, with ICDR severity classification per eye and heatmap-based explainability. The platform is integrated with DICOM/PACS hospital workflows and EHR endpoints, and is validated across six major fundus camera manufacturers (Topcon, CrystalVue, Tomey, Optomed, Canon, Nidek). The DR and AMD modules are EU-MDR Class IIb certified (CE 2265), and a Cardiovascular Disease Risk module analyzing retinal vascular biomarkers is in clinical development.

The company operates an enterprise field sales motion targeting five distinct customer segments: ophthalmologists (autonomous triage filter for routine screenings), optical stores (turning existing fundus hardware into medical revenue), hospitals and clinics (resolving specialist scarcity at point of care), population screening programs (scalable certified diagnostics), and fundus camera distributors (selling an AI-augmented ecosystem rather than commodity hardware). Revenue is generated through SaaS-style licensing and per-screening analysis fees under undisclosed enterprise pricing, with active market presence in EMEA and staged expansion into the Americas. The company is founder-led, privately held, holds ISO 27001:2023 and EN ISO 13485:2016 certifications, and has not disclosed any external funding rounds or revenue figures.

Name

Aireen

Legal name

Aireen a.s.

Website

https://aireen.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Aireen is a Prague-based medical technology company that provides EU-MDR Class IIb certified autonomous AI software for retinal screening, detecting diabetic retinopathy and AMD from 45° fundus images and serving healthcare systems across EMEA and the Americas.

Ownership category

akta.pro rank

Product category

AI Diagnostic Software / Medical Imaging AI

NAICS

Software Publishers (5132)

SIC

Ophthalmic Goods (3851), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

akta.pro secondary industry

Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)

Keywords

• Autonomous AI diagnostics
• Retinal screening software
• Diabetic retinopathy detection
• Medical imaging AI
• Fundus image analysis

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. AI Diagnostic Software (SaaS): Cloud-based software-as-a-service delivery of autonomous AI retinal screening. Revenue generated from software licensing and analysis fees per screening encounter.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Aireen develops and sells a hardware-agnostic, cloud-based autonomous AI software platform that analyzes standard 45° fundus retinal images using deep neural networks to detect diabetic retinopathy and age-related macular degeneration, producing EU-MDR Class IIb certified clinical reports in seconds without specialist interpretation. The platform is offered as SaaS to healthcare organizations (hospitals, clinics, ophthalmologists, optical stores, screening programs) with a planned cardiovascular disease risk module under development.

Product overview

Aireen is an autonomous AI retinal screening platform consisting of a core hardware-agnostic SaaS platform plus three diagnostic modules: the DR (Diabetic Retinopathy) module and AMD (Age-related Macular Degeneration) module are both EU-MDR Class IIb certified and on market, while the CVD Risk (Cardiovascular Disease Risk) module is in clinical development. The platform analyzes standard 45° fundus images using deep neural networks trained on nearly 1,000,000 annotated retinal scans, delivering certified clinical reports in seconds without specialist interpretation. Compatible with multiple fundus camera manufacturers (Topcon, CrystalVue, Tomey, Optomed, Canon, Nidek) and integrates natively with DICOM/PACS systems and EHR endpoints.

Differentiator

Problem solved

Functional benefit

Products and services

• Aireen Platform Hardware-agnostic autonomous AI retinal screening SaaS platform that analyzes standard 45° fundus images using deep neural networks trained on nearly 1,000,000 annotated retinal scans and delivers CE MDR Class IIb certified diagnostic outputs in seconds without specialist review. Targeting hospitals, clinics, ophthalmologists, optical stores, and screening programs.
• Aireen DR (Diabetic Retinopathy) Module EU-MDR Class IIb certified autonomous screening module that detects signs of diabetic retinopathy (microaneurysms, hemorrhages, hard exudates, nerve fiber layer abnormalities) from a single or multiple 45° fundus images per eye. Achieves 94.0% sensitivity and 90.7% specificity vs. expert panel and is approved for use by any healthcare professional.
• Aireen AMD (Age-related Macular Degeneration) Module EU-MDR Class IIb certified autonomous screening module that detects early signs of age-related macular degeneration — including drusen and pigment abnormalities — from the same single 45° fundus image capture as the DR module. Approved for use by any healthcare professional.

Quantifiable outcome

• 94.0% sensitivity, 90.7% specificity, 86.3% PPV vs. expert panel (n=1,274) — outperforms retina specialists (87.1% sensitivity, 81.2% specificity) and general ophthalmologists (90.1% sensitivity, 76.6% specificity)
• +1 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability6 records

Feature7 records

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Digital Diagnostics: Digital Diagnostics pioneered autonomous AI diagnostics with IDx-DR (now LumineticsCore), the first FDA-authorized autonomous AI diagnostic. Direct peer in autonomous DR screening for primary care with similar hardware-agnostic fundus integration.
• AEYE Health: AEYE Health develops AEYE-DS and AEYE-HD, FDA-cleared autonomous AI screening for DR and glaucomatous optic neuropathy from fundus images. Direct peer targeting similar non-ophthalmologist workflows and primary care channels.
• Eyenuk: Eyenuk develops EyeArt, the most widely deployed FDA-cleared autonomous AI for diabetic retinopathy screening. Directly comparable to Aireen DR on product, indication, customer base (PCPs/optical chains), and per-scan SaaS business model.
• RetinaLyze: RetinaLyze provides cloud-based AI screening for diabetic retinopathy and AMD from fundus images across European and emerging markets. Direct peer in autonomous AI screening SaaS, with overlapping ophthalmology and screening-program customer segments.

Broad incumbents

• Verily (Alphabet): Verily has published research on AI retinal biomarkers for systemic disease risk and pursues ophthalmic applications as part of a broader precision health portfolio. Larger incumbent in adjacent AI retinal imaging with deeper capital resources.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a global incumbent in ophthalmic imaging and diagnostics including fundus and OCT systems. Larger established player in the broader ophthalmic device category that Aireen operates within.

Emerging players

• Toku Eyes: Toku Eyes develops AI retinal screening for cardiovascular risk assessment from fundus images. Emerging player with overlapping CVD-pipeline indication focus and similar SaaS delivery model targeting primary care.
• Tesseract Health (Tesseract iC): Tesseract Health is developing AI-enabled retinal imaging diagnostics for systemic and ocular disease screening. Emerging player with overlapping indication roadmap (oculomics) and similar multi-camera integration philosophy.
• Remidio Innovative Solutions: Remidio combines smartphone and tabletop fundus cameras with AI-based DR screening. Emerging player targeting the same non-ophthalmologist screening workflows as Aireen, with comparable emerging-market focus.

Others

• Optomed: Optomed manufactures handheld and tabletop fundus cameras (e.g., Aurora) and is an Aireen integration partner. Adjacent enabling player — supplies the hardware that Aireen's software analyzes and bundles AI as a value-add.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aireen
• Xx.com/AireenAi

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aireen